Lacnotuzumab - Novartis Oncology

Drug Profile

Lacnotuzumab - Novartis Oncology

Alternative Names: MCS110

Latest Information Update: 21 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Dana-Farber Cancer Institute; Novartis; Novartis Oncology
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Macrophage colony stimulating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Giant cell tumour of tendon sheath; Pigmented villonodular synovitis
  • Phase I/II Malignant melanoma; Solid tumours
  • Discontinued Bone metastases; Prostate cancer

Most Recent Events

  • 03 Oct 2018 Seoul National University Hospital plans a phase II trial for Gastric Cancer (Combination therapy, Unresectable, Recurrent, Second-line therapy or greater) in South Korea (NCT03694977)
  • 24 Jun 2018 Biomarkers information updated
  • 22 Jun 2018 Phase-I/II clinical trials in Malignant melanoma (Late-stage disease, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT03455764)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top